Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.

Previously, we demonstrated that allopregnanolone (APα) promoted proliferation of rodent and human neural progenitor cells in vitro. Further, we demonstrated that APα promoted neurogenesis in the hippocampal subgranular zone (SGZ) and reversed learning and memory deficits in the male triple transgen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shuhua Chen, Jun Ming Wang, Ronald W Irwin, Jia Yao, Lifei Liu, Roberta Diaz Brinton
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8bf4c0a07ee34daeab364d46be5057f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8bf4c0a07ee34daeab364d46be5057f1
record_format	dspace
spelling	oai:doaj.org-article:8bf4c0a07ee34daeab364d46be5057f12021-11-18T06:47:00ZAllopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.1932-620310.1371/journal.pone.0024293https://doaj.org/article/8bf4c0a07ee34daeab364d46be5057f12011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21918687/?tool=EBIhttps://doaj.org/toc/1932-6203Previously, we demonstrated that allopregnanolone (APα) promoted proliferation of rodent and human neural progenitor cells in vitro. Further, we demonstrated that APα promoted neurogenesis in the hippocampal subgranular zone (SGZ) and reversed learning and memory deficits in the male triple transgenic mouse model of Alzheimer's (3xTgAD). In the current study, we determined the efficacy of APα to promote the survival of newly generated neural cells while simultaneously reducing Alzheimer's disease (AD) pathology in the 3xTgAD male mouse model. Comparative analyses between three different APα treatment regimens indicated that APα administered 1/week for 6 months was maximally efficacious for simultaneous promotion of neurogenesis and survival of newly generated cells and reduction of AD pathology. We further investigated the efficacy of APα to impact Aβ burden. Treatment was initiated either prior to or post intraneuronal Aβ accumulation. Results indicated that APα administered 1/week for 6 months significantly increased survival of newly generated neurons and simultaneously reduced Aβ pathology with greatest efficacy in the pre-pathology treatment group. APα significantly reduced Aβ generation in hippocampus, cortex, and amygdala, which was paralleled by decreased expression of Aβ-binding-alcohol-dehydrogenase. In addition, APα significantly reduced microglia activation as indicated by reduced expression of OX42 while increasing CNPase, an oligodendrocyte myelin marker. Mechanistic analyses indicated that pre-pathology treatment with APα increased expression of liver-X-receptor, pregnane-X-receptor, and 3-hydroxy-3-methyl-glutaryl-CoA-reductase (HMG-CoA-R), three proteins that regulate cholesterol homeostasis and clearance from brain. Together these findings provide preclinical evidence for the optimal treatment regimen of APα to achieve efficacy as a disease modifying therapeutic to promote regeneration while simultaneously decreasing the pathology associated with Alzheimer's disease.Shuhua ChenJun Ming WangRonald W IrwinJia YaoLifei LiuRoberta Diaz BrintonPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 8, p e24293 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shuhua Chen Jun Ming Wang Ronald W Irwin Jia Yao Lifei Liu Roberta Diaz Brinton Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.
description	Previously, we demonstrated that allopregnanolone (APα) promoted proliferation of rodent and human neural progenitor cells in vitro. Further, we demonstrated that APα promoted neurogenesis in the hippocampal subgranular zone (SGZ) and reversed learning and memory deficits in the male triple transgenic mouse model of Alzheimer's (3xTgAD). In the current study, we determined the efficacy of APα to promote the survival of newly generated neural cells while simultaneously reducing Alzheimer's disease (AD) pathology in the 3xTgAD male mouse model. Comparative analyses between three different APα treatment regimens indicated that APα administered 1/week for 6 months was maximally efficacious for simultaneous promotion of neurogenesis and survival of newly generated cells and reduction of AD pathology. We further investigated the efficacy of APα to impact Aβ burden. Treatment was initiated either prior to or post intraneuronal Aβ accumulation. Results indicated that APα administered 1/week for 6 months significantly increased survival of newly generated neurons and simultaneously reduced Aβ pathology with greatest efficacy in the pre-pathology treatment group. APα significantly reduced Aβ generation in hippocampus, cortex, and amygdala, which was paralleled by decreased expression of Aβ-binding-alcohol-dehydrogenase. In addition, APα significantly reduced microglia activation as indicated by reduced expression of OX42 while increasing CNPase, an oligodendrocyte myelin marker. Mechanistic analyses indicated that pre-pathology treatment with APα increased expression of liver-X-receptor, pregnane-X-receptor, and 3-hydroxy-3-methyl-glutaryl-CoA-reductase (HMG-CoA-R), three proteins that regulate cholesterol homeostasis and clearance from brain. Together these findings provide preclinical evidence for the optimal treatment regimen of APα to achieve efficacy as a disease modifying therapeutic to promote regeneration while simultaneously decreasing the pathology associated with Alzheimer's disease.
format	article
author	Shuhua Chen Jun Ming Wang Ronald W Irwin Jia Yao Lifei Liu Roberta Diaz Brinton
author_facet	Shuhua Chen Jun Ming Wang Ronald W Irwin Jia Yao Lifei Liu Roberta Diaz Brinton
author_sort	Shuhua Chen
title	Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.
title_short	Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.
title_full	Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.
title_fullStr	Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.
title_full_unstemmed	Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.
title_sort	allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of alzheimer's disease.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/8bf4c0a07ee34daeab364d46be5057f1
work_keys_str_mv	AT shuhuachen allopregnanolonepromotesregenerationandreducesbamyloidburdeninapreclinicalmodelofalzheimersdisease AT junmingwang allopregnanolonepromotesregenerationandreducesbamyloidburdeninapreclinicalmodelofalzheimersdisease AT ronaldwirwin allopregnanolonepromotesregenerationandreducesbamyloidburdeninapreclinicalmodelofalzheimersdisease AT jiayao allopregnanolonepromotesregenerationandreducesbamyloidburdeninapreclinicalmodelofalzheimersdisease AT lifeiliu allopregnanolonepromotesregenerationandreducesbamyloidburdeninapreclinicalmodelofalzheimersdisease AT robertadiazbrinton allopregnanolonepromotesregenerationandreducesbamyloidburdeninapreclinicalmodelofalzheimersdisease
_version_	1718424428216320000

Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.

Ejemplares similares